Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

This study looks at whether a blood test measuring circulating tumor DNA (ctDNA — tiny fragments of cancer DNA in the bloodstream) combined with PET scans can predict how well patients with a type of aggressive blood cancer called DLBCL (diffuse large B-cell lymphoma) will respond to standard chemotherapy. The goal is to help doctors personalize treatment earlier. **You may be eligible if...** - You are 18 or older - You have newly diagnosed DLBCL (a type of aggressive lymphoma) confirmed by biopsy - You have not received any prior treatment for lymphoma **You may NOT be eligible if...** - You have received prior lymphoma treatment - Your cancer is a different type of lymphoma - You have serious organ problems that would affect the study tests Talk to your doctor to see if this trial is right for you.